IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0238723.html
   My bibliography  Save this article

Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study

Author

Listed:
  • Yoshiki Ishibashi
  • Rie Nishitani
  • Akiyoshi Shimura
  • Ayano Takeuchi
  • Mamoru Touko
  • Takashi Kato
  • Sahoko Chiba
  • Keiko Ashidate
  • Nobuo Ishiwata
  • Tomoyasu Ichijo
  • Masataka Sasabe

Abstract

The aim of this study was to examine the risk of falls associated with the use of non-gamma amino butyric acid (GABA) sleep medications, suvorexant and ramelteon. This case-control and case-crossover study was performed at the Kudanzaka Hospital, Chiyoda Ward, Tokyo. A total of 325 patients who had falls and 1295 controls matched by sex and age were included. The inclusion criteria for the case group were hospitalized patients who had their first fall and that for the control were patients who were hospitalized and did not have a fall, between January 2016 and November 2018. The internal sleep medications administered were classified as suvorexant, ramelteon, non-benzodiazepines, benzodiazepines, or kampo. In the case-control study, age, sex, clinical department, the fall down risk score, and hospitalized duration were adjusted in the logistic regression model. In the case-control study, multivariable logistic regression showed that the use of suvorexant (odds ratio [OR]: 2.61, 95% confidence interval [CI]: 1.29–5.28), nonbenzodiazepines (OR: 2.49, 95% CI: 1.73–3.59), and benzodiazepines (OR: 1.65, 95% CI: 1.16–2.34) was significantly associated with an increased OR of falls. However, the use of ramelteon (OR: 1.40, 95% CI: 0.60–3.16) and kampo (OR: 1.55, 95% CI: 0.75–3.19) was not significantly associated with an increased OR of falls. In the case-crossover study, the use of suvorexant (OR: 1.78, 95% CI: 1.05–3.00) and nonbenzodiazepines (OR: 1.63, 95% CI: 1.17–2.27) was significantly associated with an increased OR of falls. Similar patterns were observed in several sensitivity analyses. It was suggested that suvorexant increases the OR of falls. This result is robust in various analyses. This study showed that the risk of falls also exists for non-GABA sleep medication, suvorexant, and thus it is necessary to carefully prescribe hypnotic drugs under appropriate assessment.

Suggested Citation

  • Yoshiki Ishibashi & Rie Nishitani & Akiyoshi Shimura & Ayano Takeuchi & Mamoru Touko & Takashi Kato & Sahoko Chiba & Keiko Ashidate & Nobuo Ishiwata & Tomoyasu Ichijo & Masataka Sasabe, 2020. "Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study," PLOS ONE, Public Library of Science, vol. 15(9), pages 1-12, September.
    • Handle: RePEc:plo:pone00:0238723
    DOI: 10.1371/journal.pone.0238723
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238723
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0238723&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0238723?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Rose Sherri & van der Laan Mark J., 2009. "Why Match? Investigating Matched Case-Control Study Designs with Causal Effect Estimation," The International Journal of Biostatistics, De Gruyter, vol. 5(1), pages 1-26, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ben Klemens, 2022. "An analysis of US domestic migration via subset-stable measures of administrative data," Journal of Computational Social Science, Springer, vol. 5(1), pages 351-382, May.
    2. Yu-Jen Cheng & Mei-Cheng Wang, 2012. "Estimating Propensity Scores and Causal Survival Functions Using Prevalent Survival Data," Biometrics, The International Biometric Society, vol. 68(3), pages 707-716, September.
    3. Rose Sherri & van der Laan Mark J., 2011. "A Targeted Maximum Likelihood Estimator for Two-Stage Designs," The International Journal of Biostatistics, De Gruyter, vol. 7(1), pages 1-21, March.
    4. van der Laan Mark J. & Petersen Maya & Zheng Wenjing, 2013. "Estimating the Effect of a Community-Based Intervention with Two Communities," Journal of Causal Inference, De Gruyter, vol. 1(1), pages 83-106, June.
    5. van der Laan Mark J., 2010. "Targeted Maximum Likelihood Based Causal Inference: Part I," The International Journal of Biostatistics, De Gruyter, vol. 6(2), pages 1-45, February.
    6. Christopher Vahl & Qing Kang, 2015. "Analysis of an outcome-dependent enriched sample: hypothesis tests," Statistical Methods & Applications, Springer;Società Italiana di Statistica, vol. 24(3), pages 387-409, September.
    7. van der Laan Mark J. & Gruber Susan, 2010. "Collaborative Double Robust Targeted Maximum Likelihood Estimation," The International Journal of Biostatistics, De Gruyter, vol. 6(1), pages 1-71, May.
    8. Sherri Rose & Julie Shi & Thomas G. McGuire & Sharon-Lise T. Normand, 2017. "Matching and Imputation Methods for Risk Adjustment in the Health Insurance Marketplaces," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 9(2), pages 525-542, December.
    9. Flynn, Rachel M. & Lissy, Rachel & Alicea, Stacey & Tazartes, Lisa & McKay, Mary M., 2016. "Professional development for teachers plus coaching related to school-wide suspensions for a large urban school system," Children and Youth Services Review, Elsevier, vol. 62(C), pages 29-39.
    10. van der Laan Mark J. & Gruber Susan, 2012. "Targeted Minimum Loss Based Estimation of Causal Effects of Multiple Time Point Interventions," The International Journal of Biostatistics, De Gruyter, vol. 8(1), pages 1-41, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0238723. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.